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Myo-inositol (Myo-Ins) plays an important role in thyroid function and autoimmunity. Myo-Ins is the 
precursor for the synthesis of phosphoinositides, which takes part in the phosphatidylinositol (PtdIns) 
signal transduction pathway, and it plays a decisive role in several cellular processes. In the thyroid 
cells, PtdIns is involved in the intracellular thyroid-stimulating hormone (TSH) signaling, via 
Phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3) (PIP-3). Moreover, the phosphatidyl 
inositol 3 kinases (PI3K) family of lipid kinases regulates diverse aspects of T, B, and Tregs 
lymphocyte behaviour. Different mouse models deficient for the molecules involved in PIP3 pathway 
suggest that impairment of PIP3 signaling leads to dysregulation of immune responses and, sometimes, 
autoimmunity. Studies have shown that cytokines modulate Myo-Ins in thyroid cells. Moreover, 
clinical studies have shown that after treatment with Myo-inositol plus seleniomethionine (Myo-
Ins+Se), TSH levels significantly declined in patients with subclinical hypothyroidism due to 
autoimmune thyroiditis. The treatment was accompanied by the antithyroid autoantibodies decline. 
After the treatment serum CXCL10 levels declined, confirming the immune-modulatory effect of Myo-
Ins. Additional researches are necessary in larger population to evaluate the effect on the quality of life, 
and to study the mechanism of the effect on chemokines. 
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1 Introduction 
Inositol(s) (INS) are hexahydroxycyclohexanes (C6H12O6) deriving from cyclohexane, and nine 
different stereoisomeric forms exist, constituted by a ring with six carbon atoms each bound to a 
hydroxyl group. Isomers derive from the epimerization of the six hydroxyl groups [1]. INS is the main 
element of phytates [2]. Myo-inositol (Myo-Ins) is more than 99% of the intracellular INS of most 
tissues. These molecules derive from the diet (beans, citrus fruits, except from lemon, nuts, and cereals 
with elevated bran content) [3] and endogenous biosynthesis (Myo-Ins is produced from glucose [4], 
mainly from liver and kidney). Noteworthy, Myo-Ins plays a key biological role and looks to be 
essential for our health. Myo-Ins is a precursor in the synthesis of phosphatidylinositol (PtdIns) 
polyphosphates, that have important physiological functions [5]. Cellular membranes have the 
precursor of inositol trisphosphate (InsP3), phosphatidyl-Myo-Ins, a second messenger that participates 
to the regulation of numerous signals [6]. In cells, INS derivatives constitute the structural lipids, and 
take part in crucial biochemical pathways, as glucose metabolism, regulation of cell proliferation, 
morphogenesis, fertility and cytoskeleton rearrangement [7,8]. INS are involved in hormones signaling, 
which is the case of thyroid stimulating hormone (TSH), insulin and follicle stimulating hormone 
(FSH). In thyroid, modifications and imbalances in the inositol metabolism impair steps which require 
a fine regulation in hormone biosynthesis, storage, and secretion. In thyroid cells, TSH stimulates 
inositol phosphate formation in a concentration-dependent manner [9]. Thus, it was shown that the 
action of TSH in thyroid was mediated also by another second-messenger system, in addition to cAMP.  
Both the phosphatidylinositol 4,5-bisphosphate (PiP2) and the cAMP cascade control the thyroid 
hormones (THs) synthesis. These metabolic pathways are connected to the activation and inhibition of 
the hydrogen peroxide synthesis; indeed, the thyroid gland is a unique endocrine organ requiring H2O2 
for the hormone assembly. The physiologic hydrogen peroxide production is a restrictive factor in	  the 
organification process (as for example the reaction that permits inorganic iodine to bind tyrosine 
residues by thyroid peroxidase) [10].	  If this process is impaired, several illnesses can arise; indeed, the 
overproduction and lack of H2O2 degradation may explain, at least partially, serious pathologies such as 
thyroiditis and tumors of this gland. On the other hand, the failure in the hydrogen peroxide production 
or the impairment of its positive control system may cause diseases, such as congenital hypothyroidism 
[11]. Experimental researches have shown that partial organification defects can be caused by TSH-
receptor (TSH-R) mutations, with also a complete loss of IP signaling [12].  
PI3K signaling is a complex network of interactions, that guarantee the right cell responses and to 
maintain immune homeostasis [13]. In different mouse models deficient for the molecules involved in 
PIP3 cascade it has been shown that impairment of PIP3 signaling can dysregulate immune responses 
and, sometimes, autoimmunity [14]. PI3K signaling plays a central role in determining B-cell fate 
[15]. Furthermore, the inositol poly-phosphatases are determinant for the effector and regulatory 
functions of the T-cell compartment. Moreover, PI3K controls chemokine responsiveness and antigen-
driven changes in lymphocyte trafficking. Consequently, human health can be damaged by the 
breakdown of immune system in this way giving rise to autoimmune diseases. 
 
We aim to review the role of Myo-Ins in human thyroid pathology and autoimmunity. 
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2 TSH signaling 
	  
2.1 TH biosynthesis, storage, and secretion 
TH synthesis starts with iodide uptake and binding of TSH to its cognate receptor (TSH-R); the 
TSH/TSH-R couple is the principal trophic hormone of thyrocytes [16]. TSH-R is expressed on the the 
basolateral membrane, belongs to the G-protein-coupled seven transmembrane receptor family, the 
same that includes luteinizing hormone (LH), chorionic gonadotropin (CG) and FSH.  
 
2.2 TSH/TSH-R/PKC/IP3 and TSH/TSH-R/PKA/cAMP cascades 
Once TSH binds to TSH-R, Gsα is coupled, adenylate cyclase is activated, leading to the formation of 
cyclic AMP (cAMP), and protein kinase A (PKA) is phosphorylated, activating downstream proteins 
in the nucleus and cytosol. This pathway regulates TH synthesis, thyroidal growth and differentiation. 
At elevated TSH levels, after its bond to TSH-R, Gαq/11 is stimulated and the phospholipase C-
dependent inositol phosphate Ca2+/diacylglycerol cascade (leading to the generation of inositol 1,4,5-
triphosphate [IP3]) activates H2O2 formation and iodination. IP3 rises the intracellular Ca2+ 
concentration and it is released from the endoplasmic reticulum. H2O2 is a restrictive factor in iodide 
oxidation and organification, and coupling reaction. In addition to the TSH/TSH-R/PKC/IP3 cascade 
(and agents stimulating the PI pathway), also the TSH/TSH-R/PKA/cAMP pathway activates the 
generation of H2O2, thanks to the cross-talk between the two pathways of TSH-R signaling [16]. 
Interestingly, triiodothyronine (T3) upregulates the leptin expression via phosphatidyl inositol 3 
kinases (PI3K) in adipocytes [17].  
Phospholipases also release arachidonic and linoleic acids that can be metabolized by 
lipoxigenase to form free radicals and lipid peroxides; these radicals and peroxides provide an 
inflammatory stress that can induce apoptosis. TSH, and cAMP agonists as well, protect 
thyrocytes from apoptosis that normally would be induced by H2O2 and other molecules. In 
addition to PKA, the protective effect of TSH involves PI3K, as the inhibitors of the PI3K 
promote apoptosis in thyroid cells [16,18]. 
Several cytokines alter thyrocyte growth and function, and such cytokine effects are affected by 
TSH and cAMP. Once cytokine receptors in the plasma membrane are activated, they attract the 
cytoplasmic tyrosine kinase JAK (Janus kinase), creating docking sites for SH-2-containing 
proteins like the “signal transducer and activator of transcription” (STATs); TSH 
phosphorylates STAT-3, an action that can be blocked by inhibitors of PKC, but not by 
inhibitors of PKA [18]. 
 
3 Phosphatydylinositol and lymphocytes 
 
3.1 The regulation of PIP3 cascade 
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Deletion in different members of the PtdIns signaling cascade leads to defects in natural killer (NK) 
cell repertoire expression and effector functions, in mouse models [19]. NK cells are determinant 
against autoimmunity, cancer and infection. 
PI3K regulate various aspects of lymphocyte behavior. After the involvement of antigen receptor, PI3K 
lead to the formation of 3-phosphorylated inositol lipid products, that function as membrane targeting 
signals for different proteins included in the generation of multiprotein complexes (called 
“signalosomes”), and in the formation of immune synapse. Class IA PI3K is the main subgroup in B-
cells, and if lost leads to strong defects in development and antigen reactivity, while in T-cells, both 
class IA and IB PI3K are involved in development and immune function. PI3K modulates the function 
of effector and regulatory (Tregs) T-cells, and in mice with PI3K-deficient T-cells these diverse 
functions cause unforeseen autoimmune phenotypes [13].   
Tregs prevent autoimmune and inflammatory disorders. The definition of the signal transduction 
pathways determinant for Tregs development and function is still going on. T-cell receptor (TCR), 
interleukin-2 receptor (IL-2R), and co-stimulatory receptor signaling have a key role in function 
of Tregs. After the stimulation of TCR, IL-2R, and CD28, the PI3K-regulated pathway is activated and 
leads to T-cell activation, proliferation, and cell survival. The two phosphatidylinositol phosphatases 
SHIP and PTEN negatively regulate the activation of the PIP3 cascade. Different mouse models 
deficient for the molecules involved in PIP3 cascade propose that impairment of PIP3 signaling can 
dysregulate immune responses and, sometimes, autoimmunity [14]. Moreover, PI3K controls 
chemokine responsivity and antigen-driven changes in lymphocyte trafficking. PI3K signaling is a 
complex network of interactions, that need to be compensated correctly in order to guarantee the right 
cell responses and to maintain immune homeostasis [13].  
Functionally silencing autoreactive B-cells that have eluded central tolerance checkpoints is a 
mechanism against autoimmune processes through the use of intravenous immunoglobulins that, in ex-
vivo stimulated human B-cells, suppressed PI3K signaling, that is known to play a central role in 
determining B-cell fate [15].  
    
3.2 Inositol Poly-Phosphatases and their targets in T-cell 
Recently chemical and genetic data have shown that the inositol poly-phosphatases are determinant for 
the effector and regulatory functions of the T-cell compartment. SHIP1 and SHIP1/2 (the 5'-inositol 
poly-phosphatases) can deviate PI(3,4,5)P3 to the infrequent but strong signaling phosphoinositide 
species PI(3,4)P2 and thus these SHIP1/2, and the inositol polyphosphate 4-phosphatase type I and 
type II enzymes (INPP4A and INPP4B) that deplete PI(3,4)P2 may amplify or inhibit effectors of PI3K 
signaling that are selectively recruited to and activated by PI(3,4)P2. Pharmaceutical manipulation of 
these enzymes for therapeutic purposes can be potentially efficient in disease settings where T 
cell function is a key in vivo target [20]. Mice genetically-deficient for the B isoform of the inositol 
1,4,5-trisphosphate 3-kinase (or Itpkb) have a severe defect in thymocytes differentiation and 
thus lack peripheral T cells. These Itpkb-deficient peripheral T cells have also an increased 
capacity to secrete cytokines upon stimulation [21].	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Moreover, antiphospholipid antibodies are measurable in about 5% of healthy subjects. Besides lupus 
anticoagulant, anticardiolipin, and β2-glycoprotein (the major antiphospholipid antibodies), other 
autoantibodies of the antiphospholipid antibody syndrome (APLAS), are against phosphatidic acid, 
phosphatidylcholine, phosphatidylserine, phosphatidylinositol, annexin V, and 
phosphatidylethanolamine. Antiphosphatydylinositol antibodies can hamper the intracellular PI3K 
signaling [22]. 
 
4 Myo-inositol and cytokines 
Autoimmune thyroid diseases (AITD) are T-cell-mediated organ-specific autoimmune disorders, 
resulting from a dysregulation of the immune system leading to an immune attack on the thyroid gland; 
in fact, the common pathological feature of AITD is the presence of lymphocyte infiltrates into the 
gland [23, 24]. 
The central role of chemokines and cytokines in the pathogenesis of organ specific and sytemic 
autoimmune disorders, and AITD, have been reported [25-27]. In thyroidal tissues, recruited T helper 1 
(Th1) lymphocytes can induce a higher secretion of IFN-γ and TNF-α, that stimulates CXCL10 (the 
prototype of the IFN-γ-inducible Th1 chemokines) release from thyrocytes; this leads to an 
amplification feedback loop, initiates and perpetuates the autoimmune process [28-30].  
Studies have shown that cytokines modulate myo-inositol in thyroid cells. A first study investigated the 
action of IFN-γ on the production of inositol phosphates and intracellular Ca2+ mobilization in primary 
cultures of human thyrocytes using the fluorescent Ca2+ indicator fura-2. IFN-γ increased the 
production of inositol mono-, bis-, and trisphosphates and caused a dose-dependent increase in 
intracellular Ca2+. The tyrosine protein kinase inhibitor, genistein, inhibited the production of inositol 
phosphates and the IFN-γ-induced increase of Ca2+, with no effects on ATP, suggesting that the 
mobilization of intracellular Ca2+ and the production of inositol phosphates are determinant for the 
effect of IFN-γ in human thyroid cells [31,32]. 
Whether myo-inositol might be able to modulate the chemokines production in thyroid cells remains 
to be elucidated. 
 
5 Myoinositol in autoimmune thyroiditis and hypothyroidism 
A double-blind randomized controlled trial has been conducted by Nordio et al. [33] in order to 
evaluate the efficacy of Myo-Ins and Se combination in patients with subclinical hypothyroidism. They 
enrolled 48 women having subclinical hypothyroidism and elevated serum anti-thyroglobulin (AbTg) 
antibodies levels (> 350 IU/ml). Patients were randomly divided in group A including twenty-four 
subjects treated daily with oral 83 µg Se in soft gel capsule; and in group B with twenty-four patients 
taking a combined treatment Myo-Ins 600 mg plus 83 µg Se (oral tablets, for six months). Therefore 
TSH, AbTPO, AbTg, Myo-Ins, and Se plasma concentrations were measured showing the favorable 
effect of the therapy with Se in patients affected by subclinical hypothyroidism, that is significantly 
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ameliorated by the combination with Myo-Ins. In group B a significant decline (31%) of TSH levels 
has been observed (4.4 ± 0.9 vs 3.1 ± 0.6 µIU/ml, P < 0.01), whereas no changes were seen in group A. 
AbTPO and AbTg levels significantly decreased in both groups. AbTg levels lower than the threshold 
have been found in eleven patients of group B, in treatment with Myo-Ins plus Se, vs three patients of 
the group A. Thyroid ultrasonography showed a normalized echogenicity in these patients [33].  
Another study by Morgante et al. [34] investigated on the prevalence of subclinical thyroid 
dysfunctions in infertile polycystic ovary syndrome (PCOS) patients and also evaluated if insulin 
sensitizers in insulin resistant PCOS patients could ameliorate thyroid function, upon 6 months of 
treatment. A significant high prevalence of subclinical thyroid dysfunction has been observed in PCOS 
patients, overall in those overweight, obese and with insulin resistance (IR). A treatment of six months 
with insulin sensitizers (containing Inositol) decreased TSH levels in insulin resistant PCOS patients, in 
a significant manner. 
More recently, one hundred and sixty-eight patients with HT and TSH levels between 3 and 6 µIU/ml 
were evaluated by Nordio et al. [35]. Patients were randomly divided into 2 groups; in one group they 
were treated with Myo-Ins+Se and in the other with only Se. Treatment with Myo-Ins+Se leads to a 
significative decrease of TSH, AbTPO and AbTg levels, and also to an improvement of thyroid 
hormones and personal wellbeing [35].  
Moreover we have conducted a study enrolling twenty-one Caucasian patients with newly diagnosed 
euthyroid chronic AT, treated with Myo-Ins plus Se tablets (600 mg/83 µg, assumed twice/day for six 
months). We have observed a reduction of TSH levels after the treatment. Therefore this leads to 
hypothesize that the combined treatment is effective in reducing the risk to develop hypothyroidism in 
individuals affected by AITD. We also found that anti-thyroid autoantibodies decreased after treatment, 
as well as CXCL10 levels, thus confirming the immune-modulatory effect exerted by the treatment 
[36].  
Myo-Ins exerts a favorable effect on TSH thanks to its biological role in the TSH hormone signaling. It 
is indeed able to regulate the H2O2-mediated iodination [37] and the impairment of inositol-depended 
TSH signaling cascade can lead to TSH resistance, and hypothyroidism [12]. Therefore, the treatment 
with Myo-Ins may rise the second messenger, and improve TSH sensitivity. 
IFN-γ-inducible protein 10 (IP-10), also known as CXCL10, binds to the chemokine (C-X-C motif) 
receptor 3 (CXCR3), promoting the pathogenesis of different autoimmune diseases, systemic (such as 
systemic lupus erythematosus, systemic sclerosis, mixed cryoglobulinemia, or Sjogren syndrome), or 
organ specific (such as Graves’ disease and Graves’ Ophthalmopathy, Type 1 diabetes) [28, 38, 39].  
IFN-γ stimulates CXCL10 secretion through CD4+, CD8+, and natural killer (NK), also by thyrocytes. 
Elevated CXCL10 levels in peripheral fluids are, then, a marker of Th1 orientated immune response. 
CXCL10 serum levels are high in patients affected by AT, particularly in those having a hypoechoic 
ultrasonographic pattern, that is a sign of a more severe lymphomonocytic infiltration, and in patients 
with hypothyroidism. Hence, CXCL10 may be a marker of a more aggressive and stronger 
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inflammatory response in the thyroid gland, which causes thyroid damage and thyroid dysfunction [40-
47].  
A study evaluated if blood mononuclear cells (PBMC) from Hashimoto's thyroiditis (HT) and 
control women were protected from in vitro H2O2-induced oxidative stress upon treatment with 
antioxidants. H2O2 alone reduced PBMC proliferation, and it decreased furtherly and dose-
dependently in either group, particularly with Myo-Ins+Se in HT. Vitality was reduced by H2O2 
alone in controls and in the HT patients, but it was rescued by the three additions. The Comet 
score was rised above baseline in controls and in HT women by H2O2 alone. In either group, 
genotoxicity was contrasted dose-dependently by each addition. Chemokines levels were 
increased by H2O2 alone, and more in HT women than in controls. These concentrations were 
reduced dose-dependently (often under baseline) by each addition in either group, in particular 
with Myo-Ins+Se (up to about -80% of baseline). The evaluated antioxidants exert favorable 
effects on PBMC exposed in vitro to H2O2-induced oxidative stress both in controls and HT 
women, and the association Myo-Ins+Se was the most effective [48].  
The immune-modulatory effect exerted by the combination of Myo-Ins and Se on CXCL10 suggests 
that they are capable of modulating the Th1 immune response, then these findings prompt to 
investigate on autoimmune diseases associated with the predominant Th1 immune response; the 
mechanisms need to be further explored [49, 50]. 
Moreover more recently Nordio et al. [51] carried out a retrospective, observational study 
enrolling 642 patients with suspected hypothyroidism undergoing ultrasound. In the analysis 
only patients having subclinical hypothyroidism or TSH levels borderline associated to thyroid 
nodules defined as class I and II were taken into account. The Authors concluded that a 
reduction of the size, number and elasticity score of thyroid nodules and of TSH levels was 
observed in patients with subclinical hypothyroidism after treatment with Myo-Ins plus Se [51].  
 
6 Conclusion 
Myo-inositol (Myo-Ins) plays an important role in thyroid function and autoimmunity. Myo-Ins 
is the precursor for the synthesis of phosphoinositides, is involved in the phosphatidylinositol 
(PtdIns) signal transduction cascade, and it plays a decisive role in several cellular processes.  
Several mouse models deficient for the molecules involved in PIP3 pathway suggest that 
impairment of PIP3 signaling leads to dysregulation of immune responses and, in some cases, 
autoimmunity.  
Clinical studies have shown that after treatment with Myo-Ins+Se, TSH levels significantly declined in 
patients with subclinical hypothyroidism due to autoimmune thyroiditis. The treatment was 
accompanied by the antithyroid autoantibodies levels decline. Furthermore, after the treatment serum 
CXCL10 declined, confirming the immune-modulatory effect of Myo-Ins. Additional researches are 
necessary in larger population, to evaluate the effect on the quality of life, and to study the mechanism 
at the basis of chemokines modulation. 
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